Research and Markets has announced the addition of the “Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors” report to their offering.
The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:
– Erythropoietin (EPO) & Erythr
– G-CSF & GM-CSF
– Thrombopoietin & Thrombopoies
– Coagulation Factors
– Human Growth Hormone (hGH)
– FSH, hCG and LH: Therapeutic
– Thrombolytics & Fibrinolytics
– Enzyme Replacement Therapies
Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia.
This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets.
For more information visit http://www.researchandmarkets.com
Source: Research and Markets press release